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Resumo 
 
Os doentes com diabetes mellitus tipo 2 apresentam predisposição para a retenção 
de sódio e são frequentemente hipertensos. No entanto, os mecanismos implicados na 
dificuldade do rim diabético em mobilizar o sódio são, ainda, pouco compreendidos. Os 
peptídeos da família das guanilinas estão envolvidos na regulação do transporte de 
electrólitos e água nos epitélios intestinal e renal, através da activação do receptor 
guanilato ciclase-C (GC-C) e subsequente libertação intracelular de GMPc. O objectivo do 
presente estudo foi a avaliação da actividade do sistema dos peptídeos das guanilinas 
(SPG) e do seu papel na regulação do balanço de sódio num modelo animal de diabetes 
tipo 2. 
Ratinhos machos C57BL/6 foram submetidos a uma dieta com alto teor de gordura 
e rica em hidratos de carbono simples (ratinhos diabéticos) ou a uma dieta normal (ratinhos 
controlo). A expressão renal e intestinal da guanilina (GN), uroguanilina (UGN) e do 
receptor GC-C assim como os níveis de GMPc na urina e plasma foram avaliados nos 
ratinhos controlo e diabéticos, durante a ingestão de dietas normo (NS) e hiper-salina (HS). 
Nos ratinhos diabéticos, durante a dieta NS verificou-se um aumento significativo 
da pressão arterial que foi acompanhado de redução da expressão do ARNm da GN, UGN 
e do GC-C no intestino e de aumento da expressão de ARNm da UGN no rim. A dieta HS 
induziu um aumento da expressão do ARNm da UGN no jejuno dos ratinhos controlo mas 
não nos diabéticos. Os ratinhos diabéticos apresentaram níveis urinários de GMPc 
inferiores aos controlos, em condições de dieta NS. 
Em conclusão, os nossos resultados sugerem que na diabetes tipo 2 ocorre uma 
redução da actividade intestinal do SPG que é acompanhada por um aumento 
compensatório da actividade renal do SPG. A diminuição da actividade do SPG intestinal 
na diabetes tipo 2 deve-se não só a uma redução da expressão dos peptídeos GN e UGN, 
mas também a uma redução da expressão do seu receptor, GC-C. Estes resultados sugerem 
que o SPG pode contribuir para a sensibilidade ao sódio na diabetes.  
 
Palavras-chave: Guanilina; uroguanilina; receptor GC-C; diabetes tipo 2; carga salina. 
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Abstract 
 
Type 2 diabetes mellitus patients have a predisposition for sodium retention and are 
frequently hypertensive. However, the mechanisms implied in the difficulty of the diabetic 
kidney in mobilizing sodium are still poorly understood. Guanylin peptides regulate 
electrolytes and water transport in intestinal and renal epithelia through  guanylate cyclase 
C (GC-C) receptor activation and subsequent cGMP intracellular release. The aim of the 
present study was to evaluate the activity of the Guanylin peptides system (GPS) and its 
role on the regulation of sodium balance in type 2 diabetes mouse model. 
Male C57BL/6 mice were submitted to either a high-fat high-simple carbohydrate 
diet (diabetic mice) or a normal diet (control mice). The renal and intestinal guanylin (GN), 
uroguanylin (UGN) and GC-C receptor mRNA expression as well as urinary and plasma 
cGMP were evaluated in control and diabetic mice, during normo (NS) and high-saline 
(HS) diets. 
In diabetic mice, during NS diet the increased blood pressure was accompanied by 
a reduced GN, UGN and GC-C mRNA expression in the intestine and increased UGN 
mRNA expression in the kidney. Sodium load increased UGN mRNA expression in the 
jejunum of the control mice, but not in diabetic. Urinary cGMP levels were reduced in 
diabetic mice in comparison to control mice, during NS diet. 
In conclusion, our results suggest that in type 2 diabetes a down-regulation of 
intestinal GPS is accompanied by a compensatory increase of renal GPS activity. The 
blunted intestinal GPS in type 2 diabetes is due not only to a reduced expression of GN and 
UGN peptides but also to a reduced expression of its GC-C receptor. These results suggest 
that GPS may contribute to the sodium sensitivity in diabetes. 
 
Keywords: Guanylin; uroguanylin; GC-C receptor; type 2 diabetes; sodium load. 
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Introduction 
 
Guanylin family  
 
The existence of uroguanylin (UGN) and guanylin (GN), was foreshadowed by the 
discovery of an orphan receptor guanylate cyclase in opossum kidney  
This receptor named guanylate cyclase C (GC-C) receptor is markedly activated by 
heat-stable enterotoxin (ST) peptides produced by strains of Escherichia coli, which cause 
a cholera-like form of secretory diarrhea (Field, 2003).This receptor was discovered in the 
intestinal, renal, hepatic, respiratory and testicular tissues (Forte et al., 1988, Forte et al., 
1989, White et al., 1989, Krause et al., 1990) which suggested the activity of endogenous 
ST-like peptides. The identification of GN was made by Currie and co-workers that 
purified and sequenced a rat intestinal peptide possessing properties consistent with an 
endogenous ligand for the intestinal GC-C (Currie et al., 1992). Later, UGN was isolated 
from opossum urine (Hamra et al., 1993).  
GN and UGN are closely related peptides which regulate electrolyte and water 
transport in intestinal and renal epithelia (Sindic and Schlatter, 2006a). These peptides are 
encoded by two different genes in humans, rats and mice, and are synthesized in the form 
of prepropeptides. In humans, these genes are located at chromosome 1 and are composed 
by three exons and two introns (Hill et al., 1995, Mägert et al., 1998), whereas in mice, the 
genes for GN peptides are located in chromosome 4 (Schulz, 1999). Cleavage of 
prepropeptides (preproGN – 115 amino acids; preproUGN – 112 amino acids) leads to the 
formation of proGN (94 amino acids) and proUGN (84 amino acids) (de Sauvage et al., 
1992, Wiegand et al., 1992, Mägert et al., 1998, Miyazato et al., 1996b) but only a second 
cleavage of the propeptides gives origin the bioactive GN and UGN. GN and UGN are 
heat-stable peptides with 15 to 19 amino acids (Sindic and Schlatter, 2006a). Human and 
rat GN are very similar, differing only in one amino acid (Currie et al., 1992, Hamra et al., 
1996a, Mägert et al., 1999, Sindic and Schlatter, 2005). The sequences of GN and UGN 
from various species are shown in Table 1. 
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Table 1: Differences between the amino acid sequences of GN and UGN in different 
species (adapted from Sindic and Schlatter, 2005) 
Species Guanylin Uroguanylin 
Human  PGT CEICAY AACT GC NDD CEL CVNV ACTGCL 
Rat/Mouse PNT CEICAY AACT GC TDE CEL CINV ACTGC 
 
Human GN (15 amino acids) and UGN (16 amino acids) possess two disulfide 
bonds between the cysteins in positions 4 and 12 and between positions 7 and 15, that are 
essential for their activities (de Sauvage et al., 1992, Kita et al., 1994, Nokihara et al., 
1997). GN peptide contains a tyrosin in position 9 from the N-terminus whereas UGN has 
an aspargine (Hamra et al., 1996a, Hamra et al., 1996b).  
The gastrointestinal tract is the main source of GN and UGN and contains the 
highest levels of its respective mRNAs and mature proteins among all tissues (Beltowski, 
2001). Small intestine has abundant UGN mRNAs levels whereas the large intestine is rich 
in GN mRNAs (Forte et al., 1999). In the intestine, UGN is expressed in a specific type of 
endocrine cell named enterochromaffin cells (Perkins et al., 1997, Nakazato et al., 1998). 
Human GN was detected in villus epithelial cells and Paneth cells of small intestine and in 
the superficial epithelial cells of large intestine (Date et al., 1996), namely the goblet cells 
of the colon (Li et al., 1995). The circulating GN peptides can have origin, besides the 
intestine, in kidneys and other tissues like adrenal glands, reproductive system, lung and 
pancreas (Kinoshita et al., 1990, Kinoshita et al., 1997a, Kinoshita et al., 1997b, Schulz et 
al., 1992, Miyazato et al., 1996a, Li et al., 1997, Nakazato et al., 1998).  
In plasma, GN and UGN circulate almost exclusively as prohormone – inactive 
form and are freely filtered through the glomerular barrier in the kidney (Nakazato et al., 
1994, Kuhn et al., 1993). Interestingly, proUGN is processed to its active natriuretic form 
exclusively within the renal tubules (Qian et al., 2008). Recent studies report that 
intravascularly infused proUGN induces a more effective natriuresis than UGN (Moss et 
al., 2010). The authors suggested that proUGN is converted intrarenally to an unknown 
natriuretic peptide that is distinct from UGN. Thus, the UGN signaling pathways in the gut 
and kidney appear to have diverged significantly in respect to the receptors, the ligands, 
and the propeptide processing mechanisms that are active in each tissue (Qian et al., 2011). 
So, urine contains UGN and low amounts of proUGN (Hamra et al., 1993). Regarding GN, 
very low amounts are found in urine; the explanation for this fact is unclear, but it was 
proposed that GN may be cleaved and inactivated by proteases within renal tubules (Fan et 
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al., 1997). Chymotrypsin cleaves the peptide bond in the carboxyl terminal next to the 
aromatic residues of GN peptides, but UGN and E. coli ST are cleavage resistant since 
they have asparagine residues instead of tyrosine/phenylalanine residues (Hamra et al., 
1996a, Hamra et al., 1996b). The same protease converts filtered proUGN into the active 
peptide leading to higher UGN/proUGN ratio in urine than in plasma (Hamra et al., 1993). 
Moreover, the members of this GN peptide family display an unusual form of structural 
isomerism, topoisomers A and B (Skelton et al., 1994). The B conformation of these 
peptides has been considered physiologically inert because of its very low activity when 
tested on intestinal GC-C receptors, but it was recently discovered that human UGN-B 
potently elicits renal natriuresis, being this the first time that two distinct topoisomers of a 
single peptide have been shown to have biological activity (Moss et al., 2009). The 
differences in the metabolism of GN and UGN suggest singular functions and targets. 
UGN was shown to be more natriuretic than GN (Sindic and Schlatter, 2005), since 
Fonteles and co-workers showed that in the isolated perfused rat kidney GN mainly caused 
kaliuresis and diuresis with less pronounced natriuretic effect (Fonteles et al., 1998). In 
2001, Potthast and co-workers observed that the renal expression of GN is not altered in 
animals on high sodium diet (Potthast et al., 2001). Therefore Sindic and Schlatter suggest 
that GN could act more as an intestinal kaliuretic peptide rather than as an intestinal 
natriuretic peptide (Sindic and Schlatter, 2005). 
 
Guanylin and uroguanylin receptors, signal transduction and biological actions 
 
GN and UGN act via activation of GC-C receptor and other not yet revealed GC-C 
like receptors. GC-C is mainly localized on the apical or brush border membrane of 
intestinal epithelial cells (De Jonge, 1975, Field et al., 1978, Schulz et al., 1990, Basu et 
al., 2010). The role of GC-C receptor in ST-induced diarrhea indicates that it may have a 
vital function in the maintenance of fluid-ion homeostasis in the intestine (Schulz et al., 
1997, Mann  et al., 1997, Basu et al., 2010). The importance of the GC-C gene in intestinal 
fluid secretion is evidenced in compromised GC-C transgenic mice that presented a 
reduction of intestinal fluid secretion (Schulz et al., 1997, Mann et al., 1997). Nevertheless 
some data suggest the existence of multiple genes coding for GC-C like receptors in mouse 
genome, since in GC-C–knockout mice some GC-C like receptors are still present and 
functionally active (Mann et al., 1997, Forte et al., 1999).  
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Although GC-C is the predominant receptor mediating the effects of GN peptides in 
the intestine, it plays only a minor role in the kidney, being possibly restricted to the 
proximal tubule. Along the nephron, at least three different receptors with different second 
messenger systems are activated by GN peptides which mediate complex effects on water 
and electrolytes excretion (Sindic and Schlatter, 2006a). This belief was reinforced by the 
recent suggestion by Moss and co-workers (Moss et al., 2009) that B topoisomer of human 
UGN elicits renal natriuresis via intestinal GC-C receptors independent pathway. 
Two other members of the receptor family, guanylate cyclase A (GC-A) and B 
(GC-B), were previously identified and bind specifically atrial natriuretic peptide (ANP) 
and C-type natriuretic peptide (CNP), respectively. Recently, an interaction between ANP 
and GN peptides was reported in isolated perfused rat kidney (Santos-Neto et al., 2006). 
These authors suggested that this interaction may play a contributory role in the regulation 
of kidney function in many pathophysiological states, such as in the natriuresis following 
ingestion of salty meals (Santos-Neto et al., 2006). 
The GC-C receptor influences cellular function via intracellular cyclic guanosine 
monophosphate (cGMP). In Figure 1 various pathways directly regulated by GC-C or 
modified by cGMP production are shown (Basu et al., 2010). 
 
Figure 1: GC-C signaling (from Basu et al., 2010). 
A number of studies have shown that, at the kidney level, GN, UGN and UGN-like 
peptide E. coli ST, elicits increases in urinary excretion of sodium, potassium, chloride and 
water (Fonteles et al., 1998). Activation of the GC-C receptor leads to the secretion of 
chloride and bicarbonate and to the inhibition of Na
+
 absorption, which determines water 
Assessment of guanylin peptides system in type 2 diabetes 
 
5 
 
secretion, and at the same time induces an increase in salt and water excretion in the 
kidney (Fonteles et al., 1998). This is mediated via cGMP, that activates protein kinase G 
II and/or increases intracellular cAMP via inhibition of phosphodiesterase III leading to 
activation of protein kinase A. Protein kinase G II and protein kinase A increase the 
secretion of Cl
-
, HCO3
- 
and water via activation of the cystic fibrosis transmembrane 
conductance regulator (CFTR) (Sindic and Schlatter, 2006b). When compared to GN 
peptides, ST has a stronger and uncontrolled activation of GC-C probably because it 
contains three disulfide bonds instead of two present in GN and UGN (Carpick and 
Gariepy, 1993). 
These peptides may activate different signalling pathways along the nephron and 
the intestinal tract. The hypothesis that UGN could serve as an endocrine axis (enterorenal 
axis) connecting the gastrointestinal tract to the kidney for regulation of sodium excretion 
(Forte et al., 1988) was suggested by the observations made more than three decades ago 
that oral administration of sodium induces a natriuresis that greatly exceeds the increase in 
urine sodium excretion elicited by intravenous NaCl infusion (Lennane et al., 1975). This 
hypothesis was further supported by the recent demonstration that mice deficient in UGN 
have blunted urinary sodium excretion responses to oral sodium loads in addition to 
elevated blood pressure (Lorenz et al., 2003), but are able to excrete sodium normally after 
intravenous administration of NaCl. In fact, increases in dietary sodium raise UGN mRNA 
levels in the intestine and kidney, suggesting that both endocrine and paracrine/autocrine 
actions of UGN could participate in tubular signalling mechanisms that control renal 
sodium transport (Beltowski, 2001). 
Given that the GN peptides are involved in the regulation of electrolyte and water 
transport in both intestine and kidney, one can hypothesise that changes in the 
physiological mechanisms which regulate the production and/or secretion of GN and UGN 
in the kidney and/or intestine, may occur in conditions characterized by compromised 
sodium homeostasis. In accordance, in patients with chronic renal failure and 
glomerulonephritis, increases in plasma and urine concentrations of GN and UGN were 
reported (Fukae et al., 2000, Nakazato et al., 1996, Nakazato et al., 1994). On the other 
hand, UGN was suggested to play an important role as natriuretic factor in rats with 
puromycin aminonucleoside-induced nephrotic syndrome (Kikuchi et al., 2005). Also, 
plasma proGN and proUGN were found to be elevated in patients with heart failure, 
suggesting that this novel endocrine system may contribute to the sodium homeostasis in 
this pathophysiological condition (Narayan et al., 2010). 
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Sodium handling in diabetes 
 
The World Health Organization believes that diabetes has assumed epidemic 
proportions and estimates that in 2025 there will be more than 300 million diabetic patients 
worldwide (Zimmet et al., 2001). Diabetes mellitus is known as a group of heterogeneous 
disorders characterized by hyperglycaemia and glucose intolerance. The causes may be 
insulin deficiency, impaired effectiveness of insulin action, or both (Harris and Zimmet, 
1997). There are two types of diabetes, type 1 and type 2 diabetes. In type 2 diabetes, 
insulin resistance and relative insulin deficiency are characteristic of this pathology. The 
enhanced prevalence of this type of diabetes is thought to be associated with various 
factors such as social changes, ageing, dietary changes and an unhealthy lifestyle (WHO, 
1994). Table 2 describes the several complications that can arise from establishment of 
diabetes.  
Table 2: The major diabetes complications (addapted from IDF, 2009). 
Brain and cerebral circulation 
Eyes 
 Cerebrovascular disease   
Retinopathy  
   
Heart and coronary circulation  Coronary heart disease 
   
Kidney 
 
Nephropathy 
   
Peripheral nervous system 
 
Neuropathy 
   
Lower limbs 
 
Peripheral vascular disease 
   
Diabetic foot 
 
Ulceration and amputation 
 
 
Type 2 diabetes mellitus patients have a predisposition for sodium retention and are 
frequently hypertensive (Landsberg, 1994, Segers et al., 1996). The interaction between 
hyperglycemia and hypertension is of outmost importance for clinical outcomes. Yet, how 
diabetes affects blood pressure control remains less clear. An abnormal renal sodium 
handling with sodium retention appears to play an important role in diabetes, even in the 
presence of well-preserved renal function.  
The mechanisms implied in the difficulty of the diabetic kidney to mobilize sodium 
are still poorly understood. Although no single reason has emerged, a major cause was 
suggested to result from an increase in tubular sodium reabsorption (Vallon et al., 2003). 
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In the presence of renal insufficiency, sodium sensitivity is aggravated in diabetes and 
contributes importantly to the increase of blood pressure and progression of nephropathy. 
The activity of the GN peptides system and its role on the regulation of sodium balance in 
type 2 diabetes was not previously examined. 
It was previously shown that mice subjected to a high fat high simple carbohydrate 
(HFHSC) diet present obesity, type 2 diabetes mellitus (T2DM) and hypertension (Rogers 
and Webb, 1980, Roncon-Albuquerque et al., 2008, Surwit et al., 1988). This animal 
model was considered one of the most reliable and clinically relevant experimental model 
of T2DM and was proven to be useful for mechanistic studies and as a tool for developing 
novel therapeutic interventions (Winzell and Ahren, 2004).  
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Aims 
 
On the basis of the previous considerations, the aim of the present project was to 
evaluate the GN peptides system activity in diabetes using an animal model of type 2 
diabetes, induced by ingestion of high-fat and high-simple carbohydrate diet in C57BL/6 
mice. Given that it is described that the production of GN peptides is under the influence of 
sodium present in the diet, studies were performed in conditions of normal and high 
sodium intake. Studies were carried out to evaluate changes in 1) urinary excretion of 
sodium, creatinine, urea and protein; 2) blood pressure and renal function; 3) cGMP levels 
in urine and plasma; 4) GN, UGN and GC-C mRNA expression in the kidney and the 
intestine assessed by qPCR, and 5) GN, UGN and GC-C protein expression in the kidney 
and the intestine assessed by immunohistochemistry or western blot.  
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Materials and Methods 
 
In vivo studies 
Animal model of type 2 diabetes mellitus 
 
Five-week-old male C57BL/6 mice were purchased from The Jackson Laboratory 
(Bar Harbor, Maine, USA). Animals were kept in a controlled environment under 12:12h 
light-dark cycle, at a room temperature of 22±2°C. At six weeks of age C57BL/6 mice 
were randomly assigned to either normal diet (Teklad LM-485 Mouse/Rat Sterilizable 
Diet; Madison, WT), with 4.1 kcal/g composed of 5% fat, 54% carbohydrate (ground 
corn), 19% protein, 5% fiber, 0.31% sodium and 0.85% potassium – control mice (C), or 
high-fat and high-simple carbohydrate diet (HFHSC; Diet F2685; BioServ Frenchtown, 
NJ), with 5.4 kcal/g composed of 35% fat (lard), 35% simple carbohydrate (sucrose), 20% 
protein, 0.1% fiber, 0.39% sodium and 0.56% potassium – diabetic mice (D), during 12 
weeks after diet initiation. The animals had free access to tap water and were fed ad 
libitum throughout the study.  During this period, daily quantification of body weight, 
water and caloric ingestion was performed. Glucose tolerance and insulin resistance tests 
were performed at 12 weeks.  
Blood pressure changes of these animals were characterized throughout the study. 
For this purpose blood pressure (systolic and diastolic) and heart rate were measured 
weekly in conscious restrained animals, using a photoelectric tail-cuff pulse detector (LE 
5000, Letica, Barcelona, Spain). Systolic blood pressure was assessed in conscious 
animals. From 08h00 to 10h00, mice were placed into a semi cylindrical container with 
controlled temperature (36–37°C). Animals were previously conditioned to the restrainer 
by repeating inflation–deflation cycles for 30 min every 2 weeks from the start of the 
experimental protocol. Before measurements, animals were conditioned to the restrainer by 
repeating inflation–deflation cycles for 15 min. At 12 weeks, a minimum of five reliable 
systolic blood pressure measurements were obtained for each animal and the average was 
used for further calculations. 
Glucose tolerance and insulin resistance tests were carried out at 12 weeks after diet 
initiation. A glucose tolerance test was performed after a 14h fast through a single 
intraperitoneal injection of dextrose (1.0 g/kg). Blood glucose concentration was measured 
before and 15, 30, 45, 60, 90, 120 and 150 min after injection using a blood glucose meter 
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(Freestyle Mini™ system). Insulin resistance was tested after a 6h fast through a single 
intraperitoneal injection of insulin, 1.5 U/kg (Actrapid® Novo Nordisk). Blood glucose 
measurements were made before and 15, 30, 45, 60 and 90 min after injection.  
Animal experiments were performed in accordance with the European Directive 
number 86/609, transposed to the Portuguese Law by DL 129/92 and by Portaria 1005/92. 
 
Metabolic studies during normal and high sodium intake 
 
Twelve weeks after the administration of normal or high caloric diets, the animals 
were housed in metabolic cages (Techniplast, Buguggiate-VA, Italy) under controlled 
environmental conditions for the collection of 24h urine. The control and diabetic groups 
were subdivided: one group of animals received tap water (normal salt intake, NS) whereas 
the other group of animals received 1.0 % (w/v) NaCl in the drinking water (high salt 
intake, HS) for 3 days. Urine volume was gravimetrically determined. The daily sodium 
intake in normal and high sodium diets average 1 and 3 mmol, respectively. 
The experimental protocol for the induction of type 2 diabetes mellitus animal 
model, subject to normal salt or high salt intake is schematically presented in Figure 2. 
 
 
 
Figure 2: Type 2 diabetes mellitus animal model, subject to normal salt (NS) or high salt 
(HS) intake. 
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On the day of sacrifice, 72 hours after normal or high-saline oral diet, the animals 
were anaesthetised with sodium pentobarbital (50 mg.kg bw-1; ip).  Blood was collected 
directly from the heart in tubes containing lithium/heparin for later determination of plasma 
biochemical parameters.The kidneys and intestine were rapidly removed after sacrifice 
through an abdominal midline incision. The kidneys were weighed, rinsed free from blood 
with saline solution (0.9% NaCl), decapsulated and cut in half. Half of the kidney was 
immediately processed for paraffin storage. The other half was divided in fragments of 
renal cortex, immersed in RNAlater Stabilization Reagent (Qiagen, Hilden, Germany) and 
stored at -80ºC. The intestine was flushed with cold saline solution and separated into the 
following segments: jejunum and colon. Some fragments were immersed in RNAlater 
Stabilization Reagent (Qiagen, Hilden, Germany) and stored at -80ºC and other were 
processed for paraffin storage. 
 
 
In vitro studies 
Plasma and urine ionogram and biochemistry 
 
Plasma cholesterol and triglycerides as well as plasma and urine levels of sodium, 
creatinine, urea and proteins were evaluated with an automatic analyser, Cobas Mira Plus 
analyser (ABX Diagnostics, Switzerland), according to ABX diagnostic reagents 
conditions. Total proteins in plasma samples were quantified by a colorimetric test, the 
Biuret reaction. In alkaline solution, cupric ions react with proteins to form a violet-
coloured chelate complex. Urinary proteins were determined by a photometric test using 
pyrogallol red. Proteins together with pyrogallol red/molybdate form a red complex. In 
both colorimetric tests, the rate of colour formation is directly related to the protein 
concentration and is measured photometrically. Cholesterol was determined after 
enzymatic hydrolysis and oxidation, by an enzymatic photometric, the Trinder’s reaction. 
In presence of peroxidase, the H2O2 formed effects the oxidative coupling of phenol and 4-
antipyrine to form a red-coloured quinoneimine derivate. The colour intensity is directly 
related to the cholesterol concentration and is measured photometrically. The 
quantification of triglycerides was performed by enzymatic colorimetric test, GPO/PAP. 
Urea was measured by an enzymatic test UV/ urease/ GLDH method. The quantification of 
sodium was performed by ion-selective electrodes. Creatinine was measured by the Jaffé 
method, a colorimetric test that is based on the reaction of picric acid with creatinine in 
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alkaline solution to form a yellow-red-coloured complex. Creatinine clearance was 
calculated using 24-hour urine creatinine excretion. Fractional excretion (FE) of sodium 
was calculated as previously reported (Sampaio-Maia et al., 2005): 
FENa=[(UNa/PNa)/(Ucrea/Pcrea)]x100, where UNa is the urinary concentration of sodium 
(mg/L), Ucrea is the urinary creatinine concentration (mg/L), PNa is the plasma 
concentration of sodium (mg/L) and Pcrea is the plasma creatinine concentration (mg/L).  
Serum insulin was quantified by ELISA, according to the manufacturer’s instructions 
(Linco Research, St. Charles, Missouri, USA). 
 
Evaluation of guanylin, uroguanylin and GC-C receptor mRNA expression in the kidney 
and the intestine 
 
The relative quantification of GN, UGN and GC-C receptor mRNA expression was 
performed by two-step RT-qPCR (reverse transcription and quantitative real-time PCR). 
After collection, samples were quickly immersed in RNA later (Qiagen, Hilden, Germany) 
and frozen at -80ºC. Total mRNA was extracted with the trizol RNA extraction method, 
according to the manufacturer’s instructions (Invitrogen, Carlsbad, 
USA). The purity of the sample and the RNA concentration was assayed by 
spectrophotometry (Eppendorf AG, Hamburg, Germany). To evaluate the integrity, the 
RNA was separated by electrophoresis on a 1% agarose gel (SeaKem
®
 LE Agarose; Lonza, 
Cologne, Germany), and then visualized with NucliStain (National Diagnostics, Atlanta, 
USA). Total RNA of jejunum was incubated with rDNase I (DNA-free Ambion, Austin, 
Texas) and DNase I buffer at 37 °C for 30 min to digest isolated traces of genomic DNA, 
followed by additional cleaning steps, as described in manufacturer’s instructions.Reverse 
transcription was performed in a standard thermocycler (MyCycler, BioRad, Hercules, 
California, USA) with the iScript cDNA Synthesis Kit (BioRad, Hercules, California, 
USA). Reaction conditions were as follows: 5 min at 25°C, 30 min at 42°C and 5 min at 
85°C (hold at 4ºC). 
cDNA first-strand synthesis was performed in a total reaction volume of 20 µl 
containing 7.5 µl of total RNA (≈750 ng), 7.5 µl of DNase/RNase free water, 4 µl 5X 
cDNA synthesis kit buffer, 1 µl iScript enzyme mixture (BioRad, Hercules, California, 
USA). The obtained cDNA was used as a template for qPCR (MiniOpticon, BioRad) using 
SYBR green chemistry (BioRad, Hercules, California, USA), according to the 
manufacturer’s instructions. One µl cDNA was then subjected to a 25 µl PCR reaction 
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using 12.5 µl SYBR Supermix, 0.5µl of each primer (10 nm) and 10.5 µl of DNase/RNase 
free water. For each gene and tissue studied standard curves of graded dilutions from a 
randomly selected control sample were generated, for determination of efficiency of qPCR. 
β-actin mRNA was used as reference gene. Primers used for each gene analysed were 
referenced in other studies (Mann et al., 2010, Lorenz et al., 2003) or were designed with 
the bioinformatic tool Primer-BLAST http://www.ncbi.nlm.nih.gov/tools/primer-blast/ 
(Table 3).  
The primers were designed according to the following: size between 17-28 bases; 
composition between 50-60% G+C; size of the amplified fragment (<150 bp); Tms 
between 55-65ºC; 3' end of primers not complementary to avoid the formation of primer 
dimers; primers not self-complementary to avoid hairpin-like structures. The amplification 
products of each primer pair were analysed by gel electrophoresis. The conditions used in 
the qPCR reaction are described in Table 4. Reaction specificities were verified by melting 
curve analysis. 
 
Table 3: Nucleotide sequences of primers employed in qPCR. 
Gene  Primer Sequence Length 
Tm 
(ºC) 
Product lengh 
UGN 
Forward 5’ TGAGTTGGAGGAGAAGGAGATGTC 3’ 24 55,34 
87 
Reverse 5’ AAGGGCAAGGCTGGGTTATG 3’ 20 54,38 
GN 
Forward 5’ GAGTGACATCGCTTGCCTTTC 3’ 21 54,18 
78 
Reverse 5’ TGAGTTTGTTAGCCTCGTGACTTC 3’ 24 55,17 
GC-C 
Forward 5’ TGGAAGAACCACAAGCTCCCCA 3’ 22 57.74 
119 
Reverse 5’ AGCACGAGGAGGGCAATCAGC 3’ 21 59.18 
β-
Actin 
Forward 5’ GCCCCTGAGGAGCACCCTGT 3’ 20 60.18 
118 
Reverse 5’ TGGCTACGTACATGGCTGGGGT 3’ 22 59.66 
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Table 4: Conditions employed in qPCR, for amplification of the genes GC-C, GN, UGN 
and β-Actin in renal cortex, colon and jejunum. 
 
 
 
 
 
Data acquisition and analysis was performed using the CFX manager 2.0 (BioRad, 
Hercules, California, USA). 
 
 
Evaluation of uroguanilin, guanylin and GC-C protein expression by 
immunohistochemistry 
 
Immunodetection was performed in paraffin sections, 4µm thick (Microm STS HM 
340E, Walldorf, Germany). Sections were deparaffined and hydrated in alcohol decrescent 
concentrations. Endogenous peroxidase was blocked using 0,3% H2O2 in methanol for 15 
or 10 minutes and then non-specific secondary antibody binding sites were blocked by 
incubation with rabbit anti-goat serum (Santa Cruz Biotechnology, USA) for 1h at room 
temperature. Thereafter, slices were incubated with polyclonal primary antibody, rabbit 
anti-UGN (1:25; Uroguanylin C15), GN (HMW Guanylin – N16) or GC-C (1:100; K14) 
(Santa Cruz Biotechnology, USA) overnight at 4ºC. Immunostaining was carried out with 
a goat anti-rabbit secondary biotinylated antibody (1:300; Santa Cruz Biotechnology, 
USA), combined with an avidin-biotin complex (Vectastain ABC kit, Vector 
Laboratories), followed by diaminobenzidine (DAB 97% TLC, Sigma, St. Luis, MO, 
USA) and hematoxylin counterstaining. Images were obtained using a Leica DM4000B 
microscope (Wetzlar, Germany) connected to a camera Leica DFC320. The images were 
processed using Leica Application Suite software (version 2.3.1 R1). 
 
 
 
Step T (ºC) Time Cycles 
Initial denaturation 95 3’  
Denaturation 95 10’’ 
40 Annealing 60 20’’ 
Extension/elongation 72 10’’ 
Melting curve 65-95 0.1ºC/s  
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Uroguanylin, Guanylin and GC-C Semiquantitative Immunoblotting 
 
The evaluation of protein expression in renal samples was performed by Western-
blot technique. Samples were mixed in loading buffer (0,35 M tris-HCl, 4% SDS, 30% 
glycerol, 9,3% DTT, ph 6.8, 0,01% bromphenol blue) and boiled at 95ºC for 5 min. The 
samples (40µg of renal homogenates) were separated by SDS-PAGE in 12% (or 7.5% - 
GC-C) polyacrylamide gel. For immunoblotting, proteins were transferred to a 
nitrocellulose membrane and incubated with the anti-UGN, GN and GC-C polyclonal 
primary antibody (1:100; Santa Cruz, USA), overnight at 4ºC. The immunoblots were 
subsequently washed and incubated with the fluorescently labelled anti-rabbit (1:20000; 
IRDye800, Rockland, PA, USA) for 1h at room temperature and protected from light. The 
membranes were washed and imaged by scanning at 800 nm, with an Odyssey Infrared 
Imaging System (LI-COR Biosciences, Lincoln, NE, USA). To determine which band or 
staining were specific to GN peptides, two additional blots were performed: one using 
primary antibody with immunizing peptide and the other using only the secondary 
antibody. -actin expression was detected by specific primary antibody (1:10000, Santa 
Cruz Biotechnology, USA), and scanned at 700nm for normalization purpose.  
 
Evaluation of cGMP in urine and plasma levels 
 
The evaluation of the second messenger, cGMP, expression in urine and plasma 
samples was performed using cGMP assay kits (R&D Systems, Minneapolis, USA) 
following the manufacturer’s instructions (Kim et al., 2005). This assay is based on the 
competitive binding technique in which cGMP present in a sample competes with a fixed 
amount of horseradish peroxidase (HRP)-labeled cGMP for sites on a rabbit polyclonal 
antibody. During the incubation, the polyclonal antibody binds to the goat anti-rabbit 
antibody coated onto the microplate. Following a washing step to remove excess conjugate 
and unbound sample, a substrate solution is added to the wells to determine the bound 
enzyme activity. The color development is stopped and the absorbance is read at 450 nm. 
The intensity of the color is inversely proportional to the concentration of cGMP in the 
sample. 
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Statistical analysis 
 
The presented results are means ± SEM of values for the indicated number of 
determinations. Data were analysed with the softwares Microsoft Excel 2010 (Washington, 
USA) and GraphPad Prism 5 (California, USA), through the use of T-test or one way 
Anova followed by Tukey test when appropriate. A p value of less than 0.05 was 
considered statistically significant. 
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Results 
Metabolic studies 
After 12 weeks of exposure to HFHSC diet, the diabetic mice presented 
significantly increased body weight, plasma cholesterol and triglycerides when compared 
to controls, as well as hyperglycemia and hyperinsulinemia (Table 5). This was 
accompanied by glucose intolerance (Figure 3A) and insulin resistance (Figure 3B) in 
diabetic mice. Also, plasma and urinary urea were significantly reduced in diabetic mice in 
comparison to controls. No significant differences between groups were observed in 
plasma and urinary levels of proteins and sodium as well as in fractional excretion of 
sodium, creatinine clearance and kidney weight (Table 5).  
 
Table 5: Body and  kidney weight, metabolic balance and renal function in control (C) and 
diabetic (D) mice. 
  
 C D 
Body weight, g 25.2±0.4 37.3±2.0* 
Kidney weight, g 0.32±0.01 0.33±0.01 
Plasma glucose, mg/dl 144.6±8.1 166.8±7.3* 
Plasma insulin, ng/ml 0.62±0.04 1.02±0.16* 
Plasma cholesterol, mg/dl 74.5±2.4 82.4±2.4* 
Plasma triglycerides, mg/dl 25.1±2.0 36.3±1.8* 
Plasma urea, mg/dl 60.2±3.0  41.0±1.9* 
Urine urea, mg/24h 116.8±7.4 66.8±7.0* 
Plasma protein, g/l 32.8±1.2 33.1±0.9 
Urine protein, mg/24h 15.2±2.8 15.8±2.1 
Plasma Na
+
, mmol/l 138.0±2.2 138.6±2.7 
Urine Na
+
, mmol/day 0.18±0.03 0.17±0.03 
FENa+, % 1.34±0.37 1.03±0.33 
Ccreat, ml/min 0.09±0.03 0.12±0.03 
Values are means  SE; n = 6 to 8 experiments per group. Ccreat, creatinine clearance; FE, fractional excretion. 
*Significantly different from values in control mice (p<0.05). 
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Figure 3: Glucose tolerance test (A) and insulin resistance test (B) in control and diabetic 
mice. Symbols represent means of 6 to 8 experiments per group, and error bars represent SE.  *Significantly different 
from control mice (p<0.05). 
 
 
In addition, diabetic mice presented a significant increase in systolic and diastolic 
blood pressure (Figure 4).  
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Figure 4: Systolic and diastolic blood pressure in control and diabetic mice. Bars represent 
means of 6 to 8 experiments per group and error bars represent SE. *Significantly different from values in control mice 
(p<0.05). 
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Figure 5: Daily urinary levels of sodium during normal (NS, day 0) or high (HS) sodium 
intake on days one (HS-d1), two (HS-d2) and three (HS-d3) days, in control (C) and 
diabetic (D) mice. Bars or symbols represent means of 6 to 8 experiments per group and error bars represent SE. 
*Significantly different from values in control mice (C) (p<0.05). #Significantly different from values in normal 
sodium (NS) intake mice (p<0.05). 
 
Figure 5 represents the daily urinary sodium excretion during the 3 days that mice 
were subjected to high sodium intake (HS). During the first 24 hours of HS diet, the 
diabetic mice presented an urinary sodium excretion lower than control mice. However, 
during the last 2 days of HS diet, the urinary excretion was similar between control and 
diabetic mice. During the last day of HS diet, the control and diabetic mice presented a 
significant increase in urinary sodium levels as well as in fractional excretion of sodium 
(Table 6). Creatinine clearance did not differ between NS or HS diets. 
 
Table 6: Renal function and sodium handling in control (C) and diabetic (D) mice, during 
normo-saline (NS) or high-saline (HS) diet. 
 NS HS 
 C D C D 
Plasma Na
+
, mmol.l-1 138.0±2.2 138.6±2.7 141.9±1.8 138.3±1.3 
Urine Na
+
, mmol.day-1 0.18±0.03 0.17±0.03 0.59±0.11
#
 0.59±0.09
#
 
FENa+ 1.34±0.37 1.03±0.33 2.44±0.32
#
 3.00±0.40
#
 
Ccreat, ml.min-1 0.09±0.03 0.12±0.03 0.14±0.02 0.10±0.01 
Ccreat, creatinine clearence; FE, fraccional excretion.*Significantly different from control mice (p<0.05). #Significantly 
different from mice subject to normo-saline oral diet (p<0.05). 
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Evaluation of cGMP in urine and plasma levels of type 2 diabetes mouse model 
 
Urinary cGMP levels in diabetic mice were lower than in control mice, although 
differences only achieved statistical significance during NS diet (Figure 6). Neither control 
nor diabetic mice demonstrated an increased level of urinary cGMP in response to a HS 
diet (Figure 6). Plasma cGMP levels were similar between control and diabetic mice 
during NS and HS diets, and were not altered in response to a sodium load. 
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Figure 6: cGMP levels in urine (A) and plasma (B) of control (C) and diabetic (D) mice, 
during normal (NS) and high-saline (HS) diet. *Significantly different from control values (p<0.05). 
 
Evaluation of guanylin, uroguanylin and GC-C receptor mRNA expression in the kidney 
and the intestine 
 
In Figure 7 is depicted one example of the results obtained with CFX manager 2.0 
(BioRad, Hercules, California, USA), for qPCR.  
 
Figure 7: Amplification curves of β-actin and UGN genes in colon, by qPCR. 
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In renal cortex, GN mRNA expression did not present significant differences 
between control and diabetic mice, either during NS or HS diet (Figure 8). On the other 
hand, UGN mRNA expression was increased in renal cortex from diabetic mice when 
compared to control, during NS diet whereas during HS diet differences between control 
and diabetic mice did not achieve statistical significance. Additionally, no significant 
differences were observed between mice subject to NS or HS diets in respect to GN and 
UGN mRNA expression in renal cortex. GC-C mRNA expression was not detected in renal 
cortex, using qPCR. 
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Figure 8: GN (A) and UGN (B) gene expression in renal cortex from control (C) and 
diabetic (D) mice, during normo-saline (NS) or high-saline (HS) oral diet. *Significantly 
different from control mice (p<0.05). 
 
 
 
In jejunum, a significant decrease of GC-C gene expression was observed in 
diabetic mice when compared with control, both in NS and HS conditions.  This was 
accompanied by a reduction in GN and UGN gene expression in diabetic mice during HS 
oral diet but not during NS diet. Sodium load did not alter GC-C or GN gene expression in 
control and diabetic mice, but increased UGN mRNA expression in control mice (Figure 
9).  
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Figure 9: GN (A), UGN (B) and GC-C (C) 
gene expression in jejunum from control (C) 
and diabetic (D) mice, during normo-saline 
(NS) e high-saline (HS) oral diet. *Significantly 
different from control mice (p<0.05). #Significantly different 
from mice subject to NS diet (p<0.05). 
 
 
 
In colon (Figure 10), a significant decrease of GC-C mRNA expression was 
observed in diabetic mice when compared with controls, both during NS and HS 
conditions. GN mRNA expression showed the same pattern of expression as GC-C, 
presenting a significant decrease of gene expression in diabetic mice during both NS and 
HS diets. UGN mRNA expression only showed a significant decrease in diabetic mice 
subjected to NS oral diet. Sodium load did not alter mRNA of GC-C, GN and UGN in 
either control or diabetic mice. 
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Figure 10: GN (A),  UGN (B) and GC-C 
(C) gene expression in colon from control 
(C) and diabetic (D) mice, during normo-
saline (NS) e high-saline (HS) oral diet. 
*Significantly different from control mice (p<0.05). 
 
Evaluation of uroguanylin protein expression in the kidney and the intestine 
 
Two different approaches were used to evaluate GN peptides protein expression in 
kidney and intestine, namely immunohistochemistry and western-blot. Using 
immunohistochemical analysis it was possible to observe a positive staining for UGN in 
renal and colon tissues (Figures 11 and 12) and GC-C receptor in colon tissue (Figure 13). 
Given that this method does not allow the accurate quantification of proteins expression, it 
was used only as qualitative assay. Thus, we concluded that UGN is present in the kidney 
and colon of control and diabetic mice and GC-C receptor is present in the colon of both 
groups of animals. Although GC-C receptor was analyzed in the kidney using 
immunohistochemistry, no satisfactory results were obtained, so conclusions could not be 
withdrawn.  In addition, the immunohistochemical analysis was not performed in the 
Assessment of guanylin peptides system in type 2 diabetes 
 
24 
 
jejunum portions of the intestine. In respect to GN several difficulties arose during the 
optimization processes and results could not be obtained. Using western-blot technic no 
consistent results were obtained for any of the molecules tested. Figure 14 shows 
representative images of the optimization of protein expression evaluation in renal tissue 
from control and diabetic mice subjected to normal or high-saline diet, by western blot. 
The fact that GN peptides have a very low molecular weight together with the poor quality 
of the antibodies available for these peptides in the initial phase of the study contributed to 
the difficulties of these approaches. Due to time limitations, no further analyses were 
performed. 
 
Figure 11: Representative light microscopy images of immunohistochemical analysis of 
kidney paraffin slices positively stained for UGN from control (A) and diabetic (B) mice 
(400x). 
  
Figure 12: Representative light microscopy images of immunohistochemical analysis of 
colon paraffin slices positively stained for UGN from control mice (A - 100x; B - 200x). 
B 
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Figure 13: Representative light microscopy images of immunohistochemical analysis of 
colon paraffin slices positively stained for GC-C from control mice (A - 200x; B - 400x). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   M    1    2   3   4   5   6   7    8      9 10 11 12 
 
Figure 14:  Representative images of GN protein expression analysis by western-blot in 
renal cortex.  M – Protein marker; 1, 5, 9 – NSC; 2, 6, 10 – NSD; 3, 7, 11 – HSC; 4, 8, 12 – 
HSD.  A – Membrane was incubated with primary GN antibody and secondary antibody; B 
– Membrane was incubated with primary GN antibody blocked with immunizing peptide 
and secondary antibody; C – Membrane was incubated only with secondary antibody. 
 
  
B A 
15 kDa -  
25 kDa -  
50 kDa - 
A B C 
Assessment of guanylin peptides system in type 2 diabetes 
 
26 
 
Discussion 
 
To our knowledge this is the first study to characterize the GPS in type 2 diabetes. 
In comparison to control mice, diabetic mice presented reduced GN, UGN and GC-C 
mRNA expression in the intestine and increased UGN mRNA expression in the kidney. 
This represents a down-regulation of intestinal GPS which is accompanied by a 
compensatory increase of renal GPS activity.  
Given that diabetes presents whole body complications, an animal model was 
employed taking in consideration the 3 R’s policy (Refinement, Reduction and 
Replacement) during animal related procedures and experiences planning. The exposure of 
C57BL/6 mice to high-fat high-simple carbohydrate diet was accompanied by obesity, 
hyperglycemia, glucose intolerance, insulin resistance, hyperinsulinemia and hypertension 
as already described by others (Rogers and Webb, 1980, Roncon-Albuquerque et al., 2008, 
Surwit et al., 1988). This animal model is considered a reliable and clinically relevant 
experimental model for type 2 diabetes pathophysiologic studies (Winzell and Ahren, 
2004). 
In the present study, the intestinal mRNA expression of GN, UGN and GC-C 
receptor was evaluated in a proximal (jejunum) and a distal (colon) portion given that 
previous studies in rodents have shown that UGN levels are relatively high in the jejunum 
and decrease progressively towards the large intestine, whereas GN shows the opposite 
pattern (Miyazato et al., 1996a, Whitaker et al., 1997, London et al., 1997). 
During normal salt intake, both GN and UGN expressions were down-regulated in 
diabetic colon. In addition, when a sodium load was given to the mice, a reduction of the 
peptides gene expression was also observed in diabetic jejunum. This down-regulation of 
jejunal GPS after a sodium load may be related not to the reduced absolute expression of 
GN peptides in diabetic mice but instead to the up-regulation of the GN peptides in control 
mice, which has been described to occur after an oral sodium load (Potthast et al., 2001). 
However, in our data only the UGN gene expression increased significantly in control mice 
in response to an oral sodium load.  
In contrast to the intestine, the UGN gene expression was increased in the diabetic 
kidney during normal salt intake, suggesting a renal compensatory response to the reduced 
intestinal production of GN and UGN peptides. This result reinforces the occurrence of 
complementary functions between the intestine and the kidney with GPS playing a role in 
renal-intestinal cross-talk. Moreover, renal GN peptides mRNA expression did not respond 
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to oral sodium load. This result suggests that renal GPS may contribute to the 
dysfunctional sodium handling in diabetes.  
Although in our animal model of type 2 diabetes no differences were observed in 
respect to urinary sodium excretion and fractional excretion of sodium, the diabetic mice 
showed an elevated blood pressure in comparison to controls. The increase of UGN gene 
expression in diabetic kidney may contribute to sodium excretion; however, the particular 
influence of this system when viewed together with all natriuretic system of the kidney 
may be small. In accordance with this view are the reports of Narayan and co-workers 
showing that despite elevated plasma proGN and proUGN and increased urinary 
bioactivity of UGN, a reduced natriuretic response to an oral salt load is observed in 
subjects with heart failure when compared with healthy subjects (Selektor and Weber, 
2008, Narayan et al., 2010).  
Potthast and co-workers found an increase in renal mRNA expression of UGN after 
oral administration of 1% NaCl as drinking solution for 3 days (Potthast et al., 2001). This 
result was not obtained in our study. The blunted response of GN or UGN mRNA 
expression to oral sodium load was also described by other author (Carrithers et al., 2002). 
These authors justified the absence of response to high sodium load with the fact that the 
NS-group of animals received higher sodium levels than equivalent normal human levels. 
Thus this NS intake was sufficient to stimulate GN mRNA expression masking the effect 
of a HS intake (Carrithers et al., 2002). The existence of controversial results on the effect 
of HS in the regulation of the GN peptides system justifies the need for further studies to 
clarify the effect of oral sodium intake on peptide synthesis and/or secretion and the 
resultant changes in intestinal and renal transport of sodium. 
GN and UGN peptide actions are mediated by GC-C receptor in the intestine. 
Interestingly, GC-C mRNA expression was significantly reduced in both jejunum and 
colon of diabetic mice, either during normal or high sodium intake, reinforcing the down-
regulation of the intestinal GPS in diabetes. Although we were able to detect GC-C 
receptor mRNA in the intestine, it was undetectable in the kidney. These observations are 
consistent with previous studies (Qian et al., 2011) and support the well-established 
hypothesis that UGN signalling in the kidney involves a receptor that is distinct from GC-
C (Carrithers et al., 1999, Carrithers et al., 2004, Sindic and Schlatter, 2005, Sindice et al., 
2002). However, previous gene expression studies have reported GC-C expression in the 
rat kidney (Carrithers et al., 2000). Qian and co-workers suggest that this variability 
reported in the literature may reflect differences in the handling or feeding of experimental 
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animals (Qian et al., 2011). However if GC-C is not the main receptor in the kidney, it may 
regulate an indeterminate component of renal function present in some conditions (Qian et 
al., 2011). A candidate for GN peptide receptor, GC-C independent, was described by 
Lehner and co-workers (Lehner et al., 2007). In this study was observed that GN peptides 
activate PLA2 (Phospholipase A2) and inhibit ROMK (Renal outer medullary potassium 
channel) channels in HEK293 (Human embryonic kidney cells) cells transfected with the 
human GPR14 receptor (G-protein coupled receptor), which is present in mouse and 
human cortical collecting duct (Lehner et al., 2007). 
To further characterise the GN peptides system and better understand its possible 
regulatory pathways we evaluated the levels of cGMP, GC-C receptor second messenger, 
in urine and plasma in experimental diabetes. In our study we found reduced cGMP levels 
in urine of diabetic mice, despite the increase in renal UGN mRNA expression. In the 
kidney, UGN seems to activate other receptors than GC-C receptor, with cGMP-
independent signaling pathways (Potthast et al., 2001, Qian et al., 2011, Carrithers et al., 
2004). Our results are in agreement with the suggestion of Qian and co-workers that UGN 
does not stimulate renal synthesis or urinary excretion of cGMP (Qian et al., 2011). Thus, 
the reduced levels of cGMP in urine may be related to other signaling pathways that may 
be altered in the diabetic kidney. 
Another hypothesis that may justify the reduced levels of urinary cGMP observed 
in parallel to the increased renal UGN expression is UGN resistance in diabetic kidney. A 
mechanism that may be similar to the ANP resistance observed in the nephrotic syndrome 
and diabetes, which occurs after ANP binding to its receptors in the collecting duct and 
appears to result from the activation of a phosphodiesterase responsible for the catabolism 
of cGMP, the second messenger of ANP (Valentin et al., 1996) 
The present work showed altered GPS gene expression in diabetic mice, however 
this does not directly translate to the expression/activity of the corresponding proteins. 
Given that these peptides suffer a strong post-transcriptional regulation, the parallel 
evaluation of GN peptides protein expression in the tissues is critical to fully understand 
this system. An attempt to evaluate protein levels was performed by western-blot and 
immunohistochemistry but no satisfactory results were obtained. The factors underlying 
this unaccomplished goal may be related to the small size of bioactive peptides and the 
quality of commercially available antibodies. Another limitation of the study was the fact 
that GN and UGN were not measured in plasma and urine. At time of the study no specific 
immunoassays for these small molecules were available for mice. So, future work will 
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include the determination of protein expression in the analyzed tissues as well as in plasma 
and urine. 
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Conclusion 
 
Our results suggest that in type 2 diabetes a down-regulation of intestinal GPS is 
accompanied by a compensatory increase of renal GPS activity. The blunted intestinal GPS 
in type 2 diabetes is due not only to a reduced expression of GN and UGN peptides but 
also to a reduced expression of its GC-C receptor. These results suggest that GPS may 
contribute to the sodium sensitivity in diabetes. 
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